Selenium Supplementation of Patients With Cirrhosis
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to determine whether patients with liver disease can improve their nutritional selenium status by taking supplemental selenium.
| Condition | Intervention |
|---|---|
|
Healthy Liver Cirrhosis |
Drug: Selenium Supplements (essential nutrient) |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Double-Blind |
- Plasma Selenium Biomarkers
| Enrollment: | 48 |
| Study Start Date: | October 1998 |
| Study Completion Date: | November 2003 |
| Primary Completion Date: | November 2003 (Final data collection date for primary outcome measure) |
Selenium is an essential nutrient. Selenium carries out its biological functions through selenoproteins. The most abundant selenoprotein in the plasma is selenoprotein P, which is largely synthesized in the liver. Patients with liver disease often have less than half the selenoprotein P levels of normal individuals. This suggests that people with liver disease are not meeting their selenium requirements and may benefit from additional selenium.
We proposed to compare the effects of two different forms of supplemental selenium on plasma selenium levels among patients with severe liver cirrhosis and healthy individuals (controls). Patients and controls were randomly assigned to one of 3 treatment groups: 200 µg selenium per day as selenate, 200 µg selenium per day as selenomethionine, or a placebo. The intervention lasted 8 weeks. Blood was measured initially and after 2 and 4 weeks of supplementation. Selenium, selenoprotein P and glutathione peroxidase were measured in the plasma. We compared changes in selenium and selenoprotein levels between liver cirrhosis patients and healthy controls.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Healthy Adults
- Adults with Child-Pugh Class C liver cirrhosis
Exclusion Criteria:
- Diagnosis of renal failure
- Urgent need of liver transplant
- Selenium supplements of >25 µg per day during the past year
Contacts and Locations| United States, Tennessee | |
| Vanderbilt University Medical Center | |
| Nashville, Tennessee, United States, 37232 | |
| Principal Investigator: | Raymond F Burk, M.D. | Vanderbilt University |
More Information
No publications provided
| Responsible Party: | RBurk, M.D., Vanderbilt University |
| ClinicalTrials.gov Identifier: | NCT00212186 History of Changes |
| Other Study ID Numbers: | DK54819, R01DK058763, 1RO3 DK54819 |
| Study First Received: | September 19, 2005 |
| Last Updated: | March 6, 2012 |
| Health Authority: | United States: Federal Government |
Additional relevant MeSH terms:
|
Liver Cirrhosis Fibrosis Liver Diseases Digestive System Diseases Pathologic Processes Selenium Trace Elements |
Micronutrients Growth Substances Physiological Effects of Drugs Pharmacologic Actions Antioxidants Molecular Mechanisms of Pharmacological Action Protective Agents |
ClinicalTrials.gov processed this record on May 16, 2013